| Original language | English |
|---|---|
| Pages (from-to) | e506-e509 |
| Journal | Haemophilia |
| Volume | 27 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Jul 2021 |
Bibliographical note
Funding Information:L. M. Schütte, R. M. van Hest and S. C. M. Stoof have no conflicts of interest. M. H. Cnossen has received grants from governmental and societal research institutes such as NWO, ZonMW, Innovation fund, from private funds, institutional grants and unrestricted investigator research grants/educational and travel funding from the following companies over the years: Pfizer, Baxter/ Baxalta/ Shire, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis and Nordic Pharma, and has served as a member on steering boards of Roche and Bayer. All grants, awards and fees go to the institution. F. W. G. Leebeek received research funding from CSL Behring, Takeda and uniQure outside the submitted work. He is a consultant for UniQure, Takeda and BioMarin, of which fees go to the institution. He received travel fees from Sobi. He is DSMB member for a study of Roche. R. A. A. Mathôt has received grants from governmental and societal research institutes such as NWO, ZonMW and Innovation fund and unrestricted investigator research grants from Baxter/ Baxalta/ Shire, Bayer Schering Pharma and CSL Behring. He has served as advisor for Bayer, CSL Behring, Merck Sharp & Dohme, Baxter/ Baxalta/ Shire, and Zeria. All grants and fees paid to the institution. M. J. H. A. Kruip received grants from governmental and societal research institutes such as NWO, ZonMW, Innovation fund, institutional grants and unrestricted investigator research grants from Pfizer, Daiichi Sankyo, Boehringer Ingelheim and research plus speakers fee from Bayer. All grants, awards and fees go to the institution.